Everolimus Clinical Trials
38 recruitingDrug
Phase 218Phase 19Phase 38Early Phase 14Not Applicable3Phase 41
Showing 1–20 of 38 trials
Recruiting
Phase 2Phase 3
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Pancreatic Neuroendocrine Tumor (pNET)Extra-Pancreatic Neuroendocrine Tumor (epNET)
Exelixis440 enrolled117 locationsNCT06943755
Recruiting
Phase 2
Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial
Unresectable Digestive System Neuroendocrine Tumor G1Unresectable Digestive System Neuroendocrine Tumor G2Metastatic Digestive System Neuroendocrine Tumor G1+1 more
National Cancer Institute (NCI)100 enrolled39 locationsNCT05773274
Recruiting
Phase 2
Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
Lung Neuroendocrine NeoplasmAdvanced Lung Neuroendocrine TumorFunctioning Lung Neuroendocrine Tumor+9 more
National Cancer Institute (NCI)70 enrolled29 locationsNCT04665739
Recruiting
Phase 1Phase 2
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
Pediatric Cancer
Gustave Roussy, Cancer Campus, Grand Paris472 enrolled23 locationsNCT02813135
Recruiting
Phase 1Phase 2
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
Hoffmann-La Roche316 enrolled32 locationsNCT04802759
Recruiting
Phase 1
Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer
EndometrialPhase IBAvutometinib+1 more
M.D. Anderson Cancer Center31 enrolled1 locationNCT07318324
Recruiting
Phase 2
Combination of Everolimus and 177Lu-DOTATATE in the Treatment of Grades 2 and 3 Refractory Meningioma: a Phase IIb Clinical Trial
Meningioma
Central Hospital, Nancy, France28 enrolled2 locationsNCT06126588
Recruiting
Phase 1Phase 2
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
Metastatic Breast CancerHormone Receptor-Positive Breast CancerHormone Receptor Positive HER-2 Negative Breast Cancer
Ellipses Pharma95 enrolled14 locationsNCT05573126
Recruiting
Phase 1
Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)
High Grade GliomaLow-grade GliomaRecurrent World Health Organization (WHO) Grade II Glioma
University of California, San Francisco50 enrolled17 locationsNCT04485559
Recruiting
Phase 2
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Metastatic Brain TumorGlioblastomaGlioblastoma Multiforme+7 more
Nationwide Children's Hospital120 enrolled20 locationsNCT05843253
Recruiting
Early Phase 1
RESTOR: PK/PD mTORi Inhibition in Older Adults
Aging
The University of Texas Health Science Center at San Antonio194 enrolled1 locationNCT06658093
Recruiting
Phase 1
Rapalog Pharmacology (RAP PAC) Study
Aging
University of Wisconsin, Madison72 enrolled1 locationNCT05949658
Recruiting
Phase 2
Expanding Liver Transplant Immunosuppression Minimization Via Everolimus
Liver Transplant
National Institute of Allergy and Infectious Diseases (NIAID)340 enrolled8 locationsNCT06280950
Recruiting
Phase 2
Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)
Metastatic Breast Cancer
Merck Sharp & Dohme LLC120 enrolled41 locationsNCT06428396
Recruiting
Phase 3
Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.
Neuroendocrine TumorsLung Neuroendocrine NeoplasmThymus Neoplasms
Grupo Espanol de Tumores Neuroendocrinos170 enrolled27 locationsNCT05918302
Recruiting
Phase 3
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Breast Cancer
Pfizer400 enrolled202 locationsNCT07062965
Recruiting
Phase 2Phase 3
Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors
Gastroenteropancreatic Neuroendocrine Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.298 enrolled1 locationNCT07165886
Recruiting
Early Phase 1
The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy
EpilepsyDrug Resistant
Xuanwu Hospital, Beijing5 enrolled1 locationNCT07095933
Recruiting
Phase 1
EVR and EPO for Liver Transplant Tolerance
Liver Transplant
National Institute of Allergy and Infectious Diseases (NIAID)20 enrolled3 locationsNCT06832189
Recruiting
Phase 2
Resistance Training and Rapamycin to Enhance Bone Formation in Postmenopausal Women
HealthyOsteoporosis RiskOsteopenia
Odense University Hospital148 enrolled2 locationsNCT07191353